Member of the Association of American Physicians
Her scientific interests lie mostly in Autosomal dominant polycystic kidney disease, Internal medicine, Endocrinology, Renal function and Urology. Her studies deal with areas such as Kidney disease and Polycystic kidney disease as well as Autosomal dominant polycystic kidney disease. Her Internal medicine research focuses on Blood pressure and PKD1.
In her research on the topic of Blood pressure, Left ventricular hypertrophy is strongly related with Cardiology. Her Renal function research includes themes of Creatinine, Body surface area and Kidney. Her Urology study incorporates themes from Tolvaptan, Confidence interval and Albuminuria.
The scientist’s investigation covers issues in Internal medicine, Autosomal dominant polycystic kidney disease, Endocrinology, Blood pressure and Renal function. Arlene B. Chapman has included themes like Pharmacogenetics and Cardiology in her Internal medicine study. Her study in Autosomal dominant polycystic kidney disease is interdisciplinary in nature, drawing from both Urology, Kidney disease and Polycystic kidney disease.
Her Urology course of study focuses on Tolvaptan and Placebo. Her Blood pressure study frequently draws connections between related disciplines such as Pharmacology. Her research investigates the connection between Renal function and topics such as Clinical trial that intersect with issues in Intensive care medicine.
Her main research concerns Autosomal dominant polycystic kidney disease, Internal medicine, Urology, Kidney disease and Blood pressure. The various areas that Arlene B. Chapman examines in her Autosomal dominant polycystic kidney disease study include Tolvaptan, Renal function and Polycystic kidney disease. As a part of the same scientific family, she mostly works in the field of Internal medicine, focusing on Endocrinology and, on occasion, Reactive oxygen species.
Her studies in Urology integrate themes in fields like Urine and Urinary system. Her work carried out in the field of Kidney disease brings together such families of science as Bioinformatics, Nephropathy, Disease, End stage renal disease and Family history. The Blood pressure study combines topics in areas such as Beta blocker and Metoprolol.
Her primary areas of study are Autosomal dominant polycystic kidney disease, Polycystic kidney disease, Urology, Kidney Volume and Kidney disease. Autosomal dominant polycystic kidney disease is a primary field of her research addressed under Cyst. Her research investigates the connection between Polycystic kidney disease and topics such as Renal function that intersect with problems in Creatinine.
Her Urology research includes themes of Plasma renin activity, Hydrochlorothiazide, Candesartan, Chlorthalidone and Receiver operating characteristic. Her Kidney Volume research is multidisciplinary, relying on both Stage, Disease progression, Egfr decline and Cystic disease. Her research integrates issues of Alport syndrome, Nephropathy and End stage renal disease in her study of Kidney disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Tolvaptan in patients with autosomal dominant polycystic kidney disease
Vicente E. Torres;Arlene B. Chapman;Olivier Devuyst;Olivier Devuyst;Ron T. Gansevoort.
The New England Journal of Medicine (2012)
Volume Progression in Polycystic Kidney Disease
Jared J. Grantham;Vicente E. Torres;Arlene B. Chapman;Lisa M. Guay-Woodford.
The New England Journal of Medicine (2006)
The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease.
Arlene B. Chapman;Ann Johnson;Patricia A. Gabow;Robert W. Schrier.
The New England Journal of Medicine (1990)
Intracranial aneurysms in autosomal dominant polycystic kidney disease.
Arlene B. Chapman;David Rubinstein;Richard Hughes;John C. Stears.
The New England Journal of Medicine (1992)
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort1
Arlene B. Chapman;Lisa M. Guay-Woodford;Jared J. Grantham;Vicente E. Torres.
Kidney International (2003)
Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease.
Sandro Rossetti;Mark B. Consugar;Arlene B. Chapman;Vicente E. Torres.
Journal of The American Society of Nephrology (2007)
Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease
Robert W. Schrier;Kaleab Z. Abebe;Ronald D. Perrone;Vicente E. Torres.
The New England Journal of Medicine (2014)
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Arlene B. Chapman;Olivier Devuyst;Kai-Uwe Eckardt;Ron T. Gansevoort.
Kidney International (2015)
Cardiac and Renal Effects of Standard Versus Rigorous Blood Pressure Control in Autosomal-Dominant Polycystic Kidney Disease: Results of a Seven-Year Prospective Randomized Study
Robert Schrier;Kimberly McFann;Ann Johnson;Arlene Chapman.
Journal of The American Society of Nephrology (2002)
Imaging Classification of Autosomal Dominant Polycystic Kidney Disease: A Simple Model for Selecting Patients for Clinical Trials
María V. Irazabal;Laureano J. Rangel;Eric J. Bergstralh;Sara L. Osborn.
Journal of The American Society of Nephrology (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: